GenScript partners with ACT Therapeutics. (Credit: fernando zhiminaicela from Pixabay)
GenScript ProBio, the CDMO unit of GenScript Biotech, has entered into a strategic partnership with ACT Therapeutics for the development of new CAR-T cell therapies.
ACT Therapeutics is engaged in developing an advanced chimeric antigen receptor (CAR)-T cell therapy platform targeting solid tumours.
The two companies have signed a memorandum of understanding (MoU) to strengthen their cooperation in the field of cell therapy.
With the MoU, GenScript ProBio becomes a global partner of ACT therapeutics and supports the latter’s CAR-T Platform (ACT platform).
The ACT platform is an immune cell-based cell and gene therapy technology, designed to leverage virus vectors to insert genes that target cancer antigens into immune cells.
ACT Therapeutics CEO Seogkyoung-Kong said: “We have completed preparations for the ACT platform to emerge globally through a strategic partnership with GenScript ProBio. We will accelerate the development of treatments targeting refractory and intractable solid cancers.”
In addition to MoU, GenScript ProBio and ACT Therapeutics are also looking to enter into a contract for the development and production of plasmid and virus vector components.
The components will be used for the first pipeline of the ACT platform, along with the production of raw materials for the company’s subsequent pipeline.
The ACT platform is an advanced CAR-T technology developed to succeed the second-generation CAR-T cell therapy.
The second-generation CAR-T cell therapy targets existing blood cancer by tackling the immune suppression microenvironment of solid cancer and activates immune cells nearby.
GenScript ProBio said that it has deployed an advanced process for the development of virus vectors, and offers a one-stop platform for GMP production of cell and gene therapies.
GenScript ProBio CEO Brian H Min said: “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
